{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:52:20Z","timestamp":1790621540769,"version":"4.1.0"},"reference-count":157,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2017.00179","type":"journal-article","created":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T04:05:20Z","timestamp":1503547520000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":42,"title":["Oncolytic Viral Therapy for Mesothelioma"],"prefix":"10.3389","volume":"7","author":[{"given":"Daniel F.","family":"Pease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kratzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/CEJ.0b013e3282f0c0a2","article-title":"US mesothelioma patterns 1973-2002: indicators of change and insights into background rates","volume":"17","author":"Teta","year":"2008","journal-title":"Eur J Cancer Prev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.annepidem.2017.04.001","article-title":"Epidemiology of mesothelioma of the pericardium and tunica vaginalis testis","volume":"27","author":"Mezei","year":"2017","journal-title":"Ann Epidemiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1179\/2049396712Y.0000000016","article-title":"Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008","volume":"19","author":"Henley","year":"2013","journal-title":"Int J Occup Environ Health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10552-016-0838-y","article-title":"Incidence of malignant mesothelioma in Germany 2009-2013","volume":"28","author":"Lehnert","year":"2017","journal-title":"Cancer Causes Control"},{"key":"B5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/sj.bjc.6602307","article-title":"The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050","volume":"92","author":"Hodgson","year":"2005","journal-title":"Br J Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3978\/j.issn.2225-319X.2012.11.04","article-title":"Malignant pleural mesothelioma: an epidemiological perspective","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"B7","first-page":"718","article-title":"Latent period for malignant mesothelioma of occupational origin","volume":"34","author":"Lanphear","year":"1992","journal-title":"J Occup Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann Oncol"},{"key":"B9","first-page":"125","article-title":"Tumors of the pleura: mesothelial tumours","volume-title":"Pathology and Genetics of Tumors of the Lung, Pleura, Thymus, and Heart. World Health Organization Classification of Tumours","author":"Churg","year":"2004"},{"key":"B10","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jtcvs.2007.10.054","article-title":"Extrapleural pneumonectomy versus pleurectomy\/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients","volume":"135","author":"Flores","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.athoracsur.2014.09.056","article-title":"Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma","volume":"99","author":"Taioli","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J Thorac Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1067\/mtc.2001.116560","article-title":"A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma","volume":"122","author":"Rusch","year":"2001","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3978\/j.issn.2225-319X.2012.11.07","article-title":"Systematic review of trimodality therapy for patients with malignant pleural mesothelioma","volume":"1","author":"Cao","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma","volume":"34","author":"Rimner","year":"2016","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1183\/16000617.0063-2016","article-title":"Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment","volume":"25","author":"Bibby","year":"2016","journal-title":"Eur Respir Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1200\/JOP.2016.011908","article-title":"Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy","volume":"12","author":"Sugarbaker","year":"2016","journal-title":"J Oncol Pract"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1097\/JTO.0b013e31826915f1","article-title":"Initial analysis of the international association for the study of lung cancer mesothelioma database","volume":"7","author":"Rusch","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B21","first-page":"82","article-title":"Sulla scomparsa di un enorme cancro vegetante del collo dell\u2019utero senza cura chirurgia","volume":"9","author":"DePace","year":"1912","journal-title":"Ginecologia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1001\/archderm.1950.01530180083015","article-title":"Note on the experimental use of rabies vaccine for melanomatosis","volume":"62","author":"Pack","year":"1950","journal-title":"AMA Arch Derm Syphilol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/1097-0142(195611\/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7","article-title":"Studies on the use of viruses in the treatment of carcinoma of the cervix","volume":"9","author":"Huebner","year":"1956","journal-title":"Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/1097-0142(195209)5:5<1025::AID-CNCR2820050518>3.0.CO;2-Q","article-title":"Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus","volume":"5","author":"Southam","year":"1952","journal-title":"Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1357-4310(97)81456-6","article-title":"Replicating viruses as selective cancer therapeutics","volume":"2","author":"Kirn","year":"1996","journal-title":"Mol Med Today"},{"key":"B26","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/neuonc\/not310","article-title":"Glioma virus therapies between bench and bedside","volume":"16","author":"Kaufmann","year":"2014","journal-title":"Neuro Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ygyno.2011.06.021","article-title":"Oncolytic virotherapy of breast cancer","volume":"123","author":"Hartkopf","year":"2011","journal-title":"Gynecol Oncol"},{"key":"B29","first-page":"1666","article-title":"[Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]","volume":"23","author":"Xia","year":"2004","journal-title":"Ai Zheng"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1097\/JTO.0000000000000214","article-title":"Measles vaccine strains for virotherapy of non-small-cell lung carcinoma","volume":"9","author":"Patel","year":"2014","journal-title":"J Thorac Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1634\/theoncologist.7-2-106","article-title":"Viral oncolysis","volume":"7","author":"Mullen","year":"2002","journal-title":"Oncologist"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1201\/b18002","volume-title":"Gene and Cell Therapy: Therapeutic Mechanisms and Strategies","author":"Smyth Templeton","year":"2015"},{"key":"B34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/89901","article-title":"Replication-selective virotherapy for cancer: biological principles, risk management and future directions","volume":"7","author":"Kirn","year":"2001","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1006\/viro.1996.0295","article-title":"The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants","volume":"220","author":"Tollefson","year":"1996","journal-title":"Virology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6147","DOI":"10.1128\/JVI.74.13.6147-6155.2000","article-title":"Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein","volume":"74","author":"Doronin","year":"2000","journal-title":"J Virol"},{"key":"B37","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/jlb.56.2.203","article-title":"Use of suicide genes in gene therapy","volume":"56","author":"Tiberghien","year":"1994","journal-title":"J Leukoc Biol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1006\/mthe.2001.0444","article-title":"Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial","volume":"4","author":"Sung","year":"2001","journal-title":"Mol Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1089\/10430340360535788","article-title":"Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer","volume":"14","author":"Kubo","year":"2003","journal-title":"Hum Gene Ther"},{"key":"B40","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1023\/B:NEON.0000003657.95085.56","article-title":"Adenovirus\/herpes simplex-thymidine kinase\/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas","volume":"65","author":"Germano","year":"2003","journal-title":"J Neurooncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"7444","DOI":"10.1158\/1078-0432.CCR-05-0405","article-title":"Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase\/ganciclovir suicide gene therapy","volume":"11","author":"Sterman","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1073\/pnas.040557897","article-title":"Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors","volume":"97","author":"Parker","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B43","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1089\/hum.2014.069","article-title":"Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus","volume":"26","author":"Hirvinen","year":"2015","journal-title":"Hum Gene Ther"},{"key":"B44","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1053\/j.seminoncol.2005.09.007","article-title":"Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects","volume":"32","author":"Thorne","year":"2005","journal-title":"Semin Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/ijc.20866","article-title":"Oncolysis of human ovarian cancers by echovirus type 1","volume":"115","author":"Shafren","year":"2005","journal-title":"Int J Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1158\/1078-0432.CCR-05-0309","article-title":"Enhanced nectin-1 expression and herpes oncolytic sensitivity in highly migratory and invasive carcinoma","volume":"11","author":"Yu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/0092-8674(93)80071-L","article-title":"The human CD46 molecule is a receptor for measles virus (Edmonston strain)","volume":"75","author":"D\u00f6rig","year":"1993","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1158\/0008-5472.CAN-04-0884","article-title":"High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus","volume":"64","author":"Anderson","year":"2004","journal-title":"Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1128\/JVI.75.6.2972-2981.2001","article-title":"Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells","volume":"75","author":"Jakubczak","year":"2001","journal-title":"J Virol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1128\/JVI.75.5.2087-2096.2001","article-title":"Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen","volume":"75","author":"Hammond","year":"2001","journal-title":"J Virol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","first-page":"6660","DOI":"10.1038\/sj.onc.1204094","article-title":"Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer","volume":"19","author":"Kirn","year":"2000","journal-title":"Oncogene"},{"key":"B53","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3892\/ijo_00000223","article-title":"Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus","volume":"34","author":"Wilden","year":"2009","journal-title":"Int J Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1093\/emboj\/17.12.3351","article-title":"The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus","volume":"17","author":"Strong","year":"1998","journal-title":"EMBO J"},{"key":"B55","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/77558","article-title":"Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus","volume":"6","author":"Stojdl","year":"2000","journal-title":"Nat Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther"},{"key":"B57","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.274.5286.373","article-title":"An adenovirus mutant that replicates selectively in p53-deficient human tumor cells","volume":"274","author":"Bischoff","year":"1996","journal-title":"Science"},{"key":"B58","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1126\/science.1851332","article-title":"Experimental therapy of human glioma by means of a genetically engineered virus mutant","volume":"252","author":"Martuza","year":"1991","journal-title":"Science"},{"key":"B59","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1099\/0022-1317-72-3-631","article-title":"Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the \u2019a\u2019 sequence","volume":"72","author":"MacLean","year":"1991","journal-title":"J Gen Virol"},{"key":"B60","first-page":"7464","article-title":"A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy","volume":"61","author":"DeWeese","year":"2001","journal-title":"Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1089\/10430349950017725","article-title":"A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma","volume":"10","author":"Hallenbeck","year":"1999","journal-title":"Hum Gene Ther"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1002\/1097-0142(197412)34:6<1907::AID-CNCR2820340609>3.0.CO;2-4","article-title":"Treatment of human cancer with mumps virus","volume":"34","author":"Asada","year":"1974","journal-title":"Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1016\/j.vaccine.2009.03.074","article-title":"In situ adenovirus vaccination engages T effector cells against cancer","volume":"27","author":"Tuve","year":"2009","journal-title":"Vaccine"},{"key":"B64","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","article-title":"Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients","volume":"70","author":"Cerullo","year":"2010","journal-title":"Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"33165","DOI":"10.18632\/oncotarget.5320","article-title":"Vesicular stomatitis virus expressing interferon-\u03b2 is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer","volume":"6","author":"Patel","year":"2015","journal-title":"Oncotarget"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1089\/hum.2009.135","article-title":"The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon","volume":"20","author":"Prestwich","year":"2009","journal-title":"Hum Gene Ther"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1182\/blood.V97.12.3746","article-title":"Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice","volume":"97","author":"Grote","year":"2001","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","first-page":"12873","DOI":"10.1073\/pnas.0605496103","article-title":"Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses","volume":"103","author":"Fulci","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B70","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1128\/JVI.74.10.4465-4473.2000","article-title":"Expression of herpes simplex virus ICP47 and human cytomegalovirus US11 prevents recognition of transgene products by CD8(+) cytotoxic T lymphocytes","volume":"74","author":"Berger","year":"2000","journal-title":"J Virol"},{"key":"B71","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1128\/JVI.72.3.2560-2563.1998","article-title":"Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP","volume":"72","author":"Tomazin","year":"1998","journal-title":"J Virol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci Transl Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.1158\/1078-0432.CCR-14-2009","article-title":"Defining effective combinations of immune checkpoint blockade and oncolytic virotherapy","volume":"21","author":"Rojas","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.immuni.2007.09.002","article-title":"Antibodies and B cell memory in viral immunity","volume":"27","author":"D\u00f6rner","year":"2007","journal-title":"Immunity"},{"key":"B76","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/gt.2012.31","article-title":"Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses","volume":"20","author":"Peng","year":"2013","journal-title":"Gene Ther"},{"key":"B77","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/sj.gt.3302038","article-title":"Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells","volume":"10","author":"Wakimoto","year":"2003","journal-title":"Gene Ther"},{"key":"B78","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/jgm.1565","article-title":"Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients","volume":"13","author":"Raki","year":"2011","journal-title":"J Gene Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1158\/0008-5472.CAN-05-2661","article-title":"Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity","volume":"66","author":"Friedman","year":"2006","journal-title":"Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/sj.gt.3302448","article-title":"Effect of hypoxia on Ad5 infection, transgene expression and replication","volume":"12","author":"Shen","year":"2005","journal-title":"Gene Ther"},{"key":"B81","doi-asserted-by":"publisher","first-page":"10664","DOI":"10.1158\/0008-5472.CAN-07-3107","article-title":"Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus","volume":"67","author":"Mok","year":"2007","journal-title":"Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1080\/21645515.2015.1037058","article-title":"Oncolytic viruses: from bench to bedside with a focus on safety","volume":"11","author":"Buijs","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"B83","doi-asserted-by":"publisher","first-page":"14007","DOI":"10.1038\/mto.2014.7","article-title":"Molecular imaging of oncolytic viral therapy","volume":"1","author":"Haddad","year":"2015","journal-title":"Mol Ther Oncolytics"},{"key":"B84","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14712598.2016.1100162","article-title":"The use of the NIS reporter gene for optimizing oncolytic virotherapy","volume":"16","author":"Miller","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1126\/science.2173860","article-title":"Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture","volume":"250","author":"Chou","year":"1990","journal-title":"Science"},{"key":"B86","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1084\/jem.187.3.341","article-title":"Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response","volume":"187","author":"Goldsmith","year":"1998","journal-title":"J Exp Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/2051-1426-2-11","article-title":"Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma","volume":"2","author":"Kaufman","year":"2014","journal-title":"J Immunother Cancer"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.hoc.2005.09.004","article-title":"Gene therapy for malignant pleural mesothelioma","volume":"19","author":"Sterman","year":"2005","journal-title":"Hematol Oncol Clin North Am"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1089\/hum.1998.9.7-1083","article-title":"Adenovirus-mediated herpes simplex virus thymidine kinase\/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma","volume":"9","author":"Sterman","year":"1998","journal-title":"Hum Gene Ther"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/sj.cgt.7700269","article-title":"A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma","volume":"7","author":"Sterman","year":"2000","journal-title":"Cancer Gene Ther"},{"key":"B91","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-07-0403","article-title":"A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses","volume":"13","author":"Sterman","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/mt.2009.309","article-title":"A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions","volume":"18","author":"Sterman","year":"2010","journal-title":"Mol Ther"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1164\/rccm.201103-0554CR","article-title":"A trial of intrapleural adenoviral-mediated Interferon-\u03b12b gene transfer for malignant pleural mesothelioma","volume":"184","author":"Sterman","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-15-2133","article-title":"Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFN\u03b1 combined with chemotherapy","volume":"22","author":"Sterman","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors \u2013 an evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Mol Ther"},{"key":"B97","article-title":"Identifier NCT01721018, Intrapleural Administration of HSV1716 to Treat Patients with Malignant Pleural Mesothelioma; 2012 [cited 2017 Apr 4]; [about 4 screens]","year":""},{"key":"B98","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/sj.cgt.7700133","article-title":"Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation","volume":"7","author":"Mukherjee","year":"2000","journal-title":"Cancer Gene Ther"},{"key":"B99","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature10358","article-title":"Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans","volume":"477","author":"Breitbach","year":"2011","journal-title":"Nature"},{"key":"B100","article-title":"Identifier NCT01503177, Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma; 2011 [cited 2017 Apr 4]; [about 5 screens]","year":""},{"key":"B101","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1200\/JCO.2002.08.042","article-title":"Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers","volume":"20","author":"Pecora","year":"2002","journal-title":"J Clin Oncol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"5564","DOI":"10.1158\/1078-0432.CCR-10-1233","article-title":"REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer","volume":"16","author":"Comins","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B103","first-page":"555","article-title":"A phase I\/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma","volume":"9","author":"Hecht","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1038\/sj.gt.3301512","article-title":"Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial","volume":"8","author":"Reid","year":"2001","journal-title":"Gene Ther"},{"key":"B105","first-page":"2055","article-title":"Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system","volume":"54","author":"Smythe","year":"1994","journal-title":"Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/0003-4975(94)90090-6","article-title":"Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma","volume":"57","author":"Smythe","year":"1994","journal-title":"Ann Thorac Surg"},{"key":"B107","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/00000658-199507000-00013","article-title":"Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene","volume":"222","author":"Smythe","year":"1995","journal-title":"Ann Surg"},{"key":"B108","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1165\/ajrcmb.13.1.7598939","article-title":"Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer","volume":"13","author":"Hwang","year":"1995","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1089\/hum.1996.7.2-141","article-title":"Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene","volume":"7","author":"Elshami","year":"1996","journal-title":"Hum Gene Ther"},{"key":"B110","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1089\/jir.1993.13.9","article-title":"Effect of interferon-alpha 2a on malignant mesothelioma","volume":"13","author":"Christmas","year":"1993","journal-title":"J Interferon Res"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3","article-title":"Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study","volume":"83","author":"Astoul","year":"1998","journal-title":"Cancer"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1002\/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N","article-title":"Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma","volume":"74","author":"Boutin","year":"1994","journal-title":"Cancer"},{"key":"B113","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/sj.cgt.7700594","article-title":"Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma","volume":"10","author":"Cordier Kellerman","year":"2003","journal-title":"Cancer Gene Ther"},{"key":"B114","first-page":"6201","article-title":"Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity","volume":"61","author":"Odaka","year":"2001","journal-title":"Cancer Res"},{"key":"B115","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1165\/rcmb.2002-0226OC","article-title":"Efficacy of CD40 ligand gene therapy in malignant mesothelioma","volume":"29","author":"Friedlander","year":"2003","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B116","first-page":"3743","article-title":"Gene therapy using adenovirus against malignant mesothelioma","volume":"32","author":"Gotoh","year":"2012","journal-title":"Anticancer Res"},{"key":"B117","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/jgm.1486","article-title":"Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus","volume":"12","author":"Kubo","year":"2010","journal-title":"J Gene Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1111\/cas.12267","article-title":"Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma","volume":"104","author":"Takagi-Kimura","year":"2013","journal-title":"Cancer Sci"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/onc.2009.415","article-title":"A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy","volume":"29","author":"Watanabe","year":"2010","journal-title":"Oncogene"},{"key":"B120","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1089\/hum.1996.7.16-2047","article-title":"Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: a phase 1 trial (BB-IND 6274)","volume":"7","author":"Treat","year":"1996","journal-title":"Hum Gene Ther"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/80474","article-title":"An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy","volume":"6","author":"Heise","year":"2000","journal-title":"Nat Med"},{"key":"B122","first-page":"636","article-title":"Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant","volume":"73","author":"Kesari","year":"1995","journal-title":"Lab Invest"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1089\/hum.2006.17.1214","article-title":"Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver","volume":"17","author":"Kemeny","year":"2006","journal-title":"Hum Gene Ther"},{"key":"B124","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1089\/hum.2014.072","article-title":"Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors","volume":"26","author":"Gayral","year":"2015","journal-title":"Hum Gene Ther"},{"key":"B125","first-page":"466","article-title":"Use of a \"replication-restricted\" herpes virus to treat experimental human malignant mesothelioma","volume":"57","author":"Kucharczuk","year":"1997","journal-title":"Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/jgm.877","article-title":"Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses","volume":"8","author":"Adusumilli","year":"2006","journal-title":"J Gene Med"},{"key":"B127","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4161\/cbt.5.1.2237","article-title":"Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma","volume":"5","author":"Adusumilli","year":"2006","journal-title":"Cancer Biol Ther"},{"key":"B128","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1245\/s10434-006-9127-4","article-title":"Radiation-induced cellular DNA damage repair response enhances viral gene therapy efficacy in the treatment of malignant pleural mesothelioma","volume":"14","author":"Adusumilli","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/00002371-200009000-00007","article-title":"Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer","volume":"23","author":"Scholl","year":"2000","journal-title":"J Immunother"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1172\/JCI24624","article-title":"Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma","volume":"115","author":"Kaufman","year":"2005","journal-title":"J Clin Invest"},{"key":"B131","first-page":"1632","article-title":"A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer","volume":"6","author":"Eder","year":"2000","journal-title":"Clin Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev-virology-031413-085442","article-title":"Oncolytic poxviruses","volume":"1","author":"Chan","year":"2014","journal-title":"Annu Rev Virol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat Med"},{"key":"B134","article-title":"Identifier NCT02562755, Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone (PHOCUS); 2015 [cited 2017 Apr 4]; [about 4 screens]","year":""},{"key":"B135","doi-asserted-by":"publisher","first-page":"10038","DOI":"10.1158\/0008-5472.CAN-07-0146","article-title":"Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus","volume":"67","author":"Zhang","year":"2007","journal-title":"Cancer Res"},{"key":"B136","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1089\/hum.2008.036","article-title":"Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma","volume":"19","author":"Kelly","year":"2008","journal-title":"Hum Gene Ther"},{"key":"B137","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.surg.2013.06.004","article-title":"An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT\/CT imaging in an orthotopic model of malignant pleural mesothelioma","volume":"154","author":"Belin","year":"2013","journal-title":"Surgery"},{"key":"B138","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1245\/s10434-014-3651-4","article-title":"Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma","volume":"21","author":"Acuna","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1099\/0022-1317-78-8-2041","article-title":"Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation","volume":"78","author":"Vanderplasschen","year":"1997","journal-title":"J Gen Virol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"7544","DOI":"10.1073\/pnas.95.13.7544","article-title":"Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope","volume":"95","author":"Vanderplasschen","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B141","first-page":"4656","article-title":"Intraperitoneal therapy of ovarian cancer using an engineered measles virus","volume":"62","author":"Peng","year":"2002","journal-title":"Cancer Res"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/mt.2010.43","article-title":"Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers","volume":"18","author":"Liu","year":"2010","journal-title":"Mol Ther"},{"key":"B143","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.mayocp.2014.04.003","article-title":"Remission of disseminated cancer after systemic oncolytic virotherapy","volume":"89","author":"Russell","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"B144","article-title":"Identifier NCT00450814, Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma; 2007 Mar 20 [cited 2017 Apr 4]; [about 7 screens]","year":""},{"key":"B145","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.1158\/0008-5472.CAN-07-6265","article-title":"Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response","volume":"68","author":"Gauvrit","year":"2008","journal-title":"Cancer Res"},{"key":"B146","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/cgt.2010.10","article-title":"Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy","volume":"17","author":"Li","year":"2010","journal-title":"Cancer Gene Ther"},{"key":"B147","doi-asserted-by":"publisher","first-page":"44892","DOI":"10.18632\/oncotarget.6285","article-title":"Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response","volume":"6","author":"Achard","year":"2015","journal-title":"Oncotarget"},{"key":"B148","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1089\/vim.2004.17.516","article-title":"Vesicular stomatitis virus as an oncolytic vector","volume":"17","author":"Barber","year":"2004","journal-title":"Viral Immunol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"7713","DOI":"10.1158\/0008-5472.CAN-09-1013","article-title":"Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma","volume":"69","author":"Willmon","year":"2009","journal-title":"Cancer Res"},{"key":"B150","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/hum.2009.088","article-title":"Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy","volume":"21","author":"Saloura","year":"2010","journal-title":"Hum Gene Ther"},{"key":"B151","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1128\/JVI.01553-09","article-title":"Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy","volume":"84","author":"Elankumaran","year":"2010","journal-title":"J Virol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1158\/1535-7163.MCT-10-0090","article-title":"Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma","volume":"9","author":"Silberhumer","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1111\/j.1349-7006.2011.01931.x","article-title":"Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma","volume":"102","author":"Kitamura","year":"2011","journal-title":"Cancer Sci"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1097\/JTO.0b013e3182725fa4","article-title":"E1B-55 kDa-defective adenoviruses activate p53 in mesothelioma and enhance cytotoxicity of anticancer agents","volume":"7","author":"Yamanaka","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jtcvs.2003.08.034","article-title":"Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma","volume":"127","author":"Kruklitis","year":"2004","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B156","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/OV.S66091","article-title":"Oncolytic virotherapy for human malignant mesothelioma: recent advances","volume":"4","author":"Boisgerault","year":"2015","journal-title":"Oncolytic Virother"},{"key":"B157","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/14737140.2016.1191951","article-title":"Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges","volume":"16","author":"Ceresoli","year":"2016","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2017.00179\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T04:18:46Z","timestamp":1602821926000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2017.00179\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,24]]},"references-count":157,"alternative-id":["10.3389\/fonc.2017.00179"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2017.00179","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,24]]},"article-number":"179"}}